- Innate Pharma (IPH; IPHA) files its 2024 Universal Registration Document with the French AMF.
- The annual report on Form 20-F for 2024 is also filed with the US SEC.
- Innate Pharma is advancing its oncology-focused immunotherapy portfolio.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced the completion of key regulatory filings crucial for its financial transparency and investor relations. The company has filed its 2024 Universal Registration Document, known as "Document d’enregistrement universel," with the Autorité des Marchés Financiers (AMF) in France, dated April 30, 2025. Additionally, Innate Pharma has submitted its annual report on Form 20-F for 2024 to the United States Securities and Exchange Commission (SEC), reinforcing its commitment to compliance and detailed financial reporting.
The Universal Registration Document, available in French, offers a comprehensive overview of the company's operational and financial performance for the past year. Investors and stakeholders can access these detailed reports on the company's website and the respective AMF and SEC online portals.
Innate Pharma is a leading biotechnology firm centered on developing innovative immunotherapies for cancer treatment. The company leverages its ANKET® platform for NK Cell Engagers, apart from advancing its Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs) portfolios. Notably, its portfolio includes various candidates like IPH4502, a specialized ADC aimed at tackling solid tumors.
Significantly, the company continues to build strategic partnerships with major biopharmaceutical entities such as AstraZeneca and Sanofi, aiming to accelerate its research and development efforts. Headquartered in Marseille, France, with an operational base in Rockville, MD, USA, Innate Pharma maintains a firm presence on Euronext Paris and Nasdaq.
